Fresenius properly cancelled Akorn deal, court rules
Credit: iStock/kontrast-fotodesign
Healthcare company Fresenius did not breach its merger agreement with rival pharmaceutical company Akorn when it decided to terminate the $4.3 billion deal, Delaware’s Court of Chancery has ruled.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10